Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | IDH2 | P48735 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 3/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SIK1 | P57059 | 1/20 | 0.32 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.32 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4596624 | 0.86 | MAOB (0.40) | MAOBMAOAPDGFRBPDGFRANPC1 | |
| SCHEMBL4220237 | 0.82 | PRKAB2 (0.46) | MAOBMAOAPDGFRBPDGFRANPC1 | |
| SCHEMBL4608124 | 0.79 | CETP (0.39) | DRD2IDH2 | |
| SCHEMBL4596665 | 0.75 | HDAC4 (0.38) | CA12CA1CA2CA9 | |
| SCHEMBL5058627 | 0.75 | PTGS2 (0.36) | NPC1RAB9A | |
| SCHEMBL4596870 | 0.74 | DRD1 (0.37) | MAOADRD2 | |
| SCHEMBL4711430 | 0.74 | HTR7 (0.38) | NPC1RAB9A | |
| SCHEMBL4597398 | 0.74 | LMNA (0.36) | MAOBMAOANPC1RAB9A | |
| SCHEMBL4596547 | 0.73 | MAPT (0.40) | MAOANPC1RAB9A | |
| SCHEMBL4711420 | 0.73 | MAOB (0.35) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879569-A2 | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | Wyeth (US) | 2008-01-23 | — | — | EP | claimed |
| JP-2007509174-A | — | — | 2007-04-12 | — | — | JP | claimed |
| WO-2006116221-A2 | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | claimed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | claimed |
| EP-1898895-A2 | TREATMENT OF DRUG ABUSE | Wyeth (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1874750-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth Incoporated (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1871354-A1 | TREATMENT OF PAIN | Wyeth (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2007030150-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2006116148-A2 | (7-ARLYSUBSTITUTED 2, 3-DIHYDR0-1-BENZ0FURAN-2-YL) ALKYLAMINES IN THE TREATMENT' OF SUBSTANCE ABUSE | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006116171-A1 | TREATMENT OF PAIN | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | ADRA2A, HTR2A, ADRA1A | MAOB 50/4885MAOA 29/4885PDGFRB 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.